A novel bioresponsive self-immolative spacer based on aza-quinone methide reactivity for the controlled release of thiols, phenols, amines, sulfonamides or amides.


Journal

Chemical science
ISSN: 2041-6520
Titre abrégé: Chem Sci
Pays: England
ID NLM: 101545951

Informations de publication

Date de publication:
24 Apr 2024
Historique:
received: 06 03 2024
accepted: 24 03 2024
medline: 26 4 2024
pubmed: 26 4 2024
entrez: 26 4 2024
Statut: epublish

Résumé

A stimuli-sensitive linker is one of the indispensable components of prodrugs for cancer therapy as it covalently binds the drug and releases it upon external stimulation at the tumour site. Quinone methide elimination has been widely used as the key transformation to release drugs based on their nucleofugacity. The usual approach is to bind the drug to the linker as a carbamate and release it as a free amine after a self-immolative 1,6-elimination. Although this approach is very efficient, it is limited to amines (as carbamates), alcohols or phenols (as carbonates) or other acidic functional groups. We report here a self-immolative spacer capable of directly linking and releasing amines, phenols, thiols, sulfonamides and carboxyamides after a reductive stimulus. The spacer is based on the structure of (5-nitro-2-pyrrolyl)methanol (NPYM-OH), which was used for the direct alkylation of the functional groups mentioned above. The spacer is metabolically stable and has three indispensable sites for bioconjugation: the bioresponsive trigger, the conjugated 1,6 self-immolative system and a third arm suitable for conjugation with a carrier or other modifiers. Release was achieved by selective reduction of the nitro group over Fe/Pd nanoparticles (NPs) in a micellar aqueous environment (H

Identifiants

pubmed: 38665538
doi: 10.1039/d4sc01576b
pii: d4sc01576b
pmc: PMC11041255
doi:

Types de publication

Journal Article

Langues

eng

Pagination

6168-6177

Informations de copyright

This journal is © The Royal Society of Chemistry.

Déclaration de conflit d'intérêts

There are no conflicts to declare.

Auteurs

Elena Ermini (E)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.

Annalaura Brai (A)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.

Elena Cini (E)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.

Federica Finetti (F)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.

Giuseppe Giannini (G)

Translational Medicine & Clinical Pharmacology Corporate R&D - Alfasigma SpA Via Pontina, km 30400 00071 Pomezia (Roma) Italy.

Daniele Padula (D)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.

Lucrezia Paradisi (L)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.

Federica Poggialini (F)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.

Lorenza Trabalzini (L)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.

Paola Tolu (P)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.

Maurizio Taddei (M)

Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.

Classifications MeSH